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Proteomics analysis of vesicles isolated from plasma
and urine of prostate cancer patients using a multiplex,
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Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasive disease
markers. Obtaining vesicles of sufficient quality and quantity for profiling studies has, however, been a major
problem, as samples are often replete with co-isolated material that can interfere with the identification
of genuine low abundance, vesicle components. Here, we used a combination of ultracentrifugation and
size-exclusion chromatography to isolate and analyse vesicles of plasma or urine origin. We describe a sample-
handling workflow that gives reproducible, quality vesicle isolations sufficient for subsequent protein profiling.
Using a semi-quantitative aptamer-based protein array, we identified around 1,000 proteins, of which almost
400 were present at comparable quantities in plasma versus urine vesicles. Significant differences were, however,
apparent with elements like HSP90, integrin aVb5 and Contactin-1 more prevalent in urinary vesicles, while
hepatocyte growth factor activator, prostate-specific antigenantichymotrypsin complex and many others were
more abundant in plasma vesicles. This was also applied to a small set of specimens collected from men with
metastatic prostate cancer, highlighting several proteins with the potential to indicate treatment refractory
disease. The study provides a practical platform for furthering protein profiling of vesicles in prostate cancer,
and, hopefully, many other disease scenarios.
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P
rostate cancer is the most common cancer in men in
the UK, and lifetime prevalence is 1 in 8, accounting
for almost 1 quarter of new male cancer cases (1)
with 220,800 new diagnosis projected for 2015 in the USA
(2). The reliance on serum prostate-specific antigen (PSA)
levels as a mode of prostate cancer detection has been
a mixed success. While helping to identify men with early-
stage disease, its low specificity has led to a problem of
over-diagnosis and the treatment of clinically insignificant
tumours. Most diagnoses will not actually require active
interventions other than surveillance, as they would be
considered indolent. In a proportion of men, however,
the disease takes a more aggressive course and the early
identification of these cancers remains a challenge. In fact,
in a major review of gene expression data in prostate
cancer, the authors concluded that, after 10 years of
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biomarker research, the histological Gleason score re-
mains the most useful prognostic marker, and searching
for biomarkers to improve this must continue (3).
Exosomes are membrane-bounded vesicles manufac-
tured within late endosomal compartments termed multi-
vesicular endosomes, which are trafficked to the plasma
membrane releasing the preformed nanovesicles into the
extracellular space (4). The vesicles constitute a miniature
and simpler version of the parent cell in terms of the
proteome (5), but they also encapsulate a set of transcripts,
non-coding RNA, and possibly DNA, which again differ
from the cellular repertoire (6,7). Exosomes often exhibit
heightened production by cancer cells (8), and exogenous
environmental cues, such as hypoxia or other stressors, can
lead to changes in the molecular constituents of exosomes
(9,10). Dynamic changes in exosomes are functionally im-
portant, and there is strong evidence demonstrating their
roles in carcinogenesis and disease progression, through
direct activities in immune evasion, stromal activation,
angiogenesis and metastatic niche formation (11).
Exosomes mediate their influence locally and also at
distant sites within the body through entering the circula-
tion. In fact, exosomes are present within all biological
fluids including circulating plasma (12), seminal plasma,
urine (13), saliva (14), tumour effusions (15) and others.
For these reasons, exosomes have attracted considerable
interest in recent years as possible ‘‘treasure chests’’ of rele-
vant disease markers (1620); that is to say, they provide
a complex set of molecules of functional importance
in disease, in a minimally invasive manner. Although there
is enormous interest in the discovery of RNA-related
markers within biofluid-derived exosomes, there is still
considerable utility in deciphering the protein profile of
these vesicles. A notable example is the use of vesicular
Glypican-1 to provide diagnostic information in early
pancreatic cancer (17).
Performing proteomics on exosomes isolated from
biological fluids, however, is a technical challenge for
several reasons. Biological fluids, particularly blood
plasma, are extremely protein-rich, and confidently separ-
ating vesicles from non-vesicular proteins is very difficult.
The use of straightforward differential centrifugation
followed by an ultracentrifugation pelleting step provides
a vesicle-containing sample replete with high abundant
blood proteins such as albumin, complement components
and immunoglobulins. When present, these components
are notorious for confounding mass-spectrometry-based
proteomics as they mask the identification of relatively low
abundant, vesicle-associated proteins. Some more recent
attempts have utilized some traditional, but gold-standard
methods, involving ultracentrifugation on gradients, re-
sulting in significant enrichment of vesicles, revealing
greater numbers of likely vesicle-related proteins (21).
However, such gains are countered by the sample-handling
processes here that involve operator skill and are very time
consuming. The use of size-exclusion chromatography
(SEC) has been advocated as a means of separating vesicles
from proteins some time ago (22) and has seen renewed
uptake recently by the vesicle community as avesicle clean-
up method (23). The use of SEC as an up-front method
prior to mass spectrometry has indeed shown some utility,
revealing just over 100 proteins that might otherwise
not have been possible to identify (24). However, even
with very advanced mass-spectrometry instrumentation,
the inability to completely remove contaminating albumin
and other abundant biofluid proteins is limiting the
capacity to discover novel exosome proteins that can be
informative of disease.
The use of protein-array methods may offer a partial
solution to this, if the presence of contaminating protein
would have less impact in masking interesting yet low
abundance vesicular protein. One such technology plat-
form is the SOMAscan† assay, which is a multiplex
aptamer-based protein array capable of giving relative
quantity data on over 1,000 proteins (detailed by Gold
et al. (25)). Although principally designed for assaying
blood (serum/plasma), it is adaptable for other sample
types including urine, and we have previously used this
method for protein discovery in prostate cancer cell-
line derived exosomes, identifying over 300 proteins with
previously unknown associations with prostate cancer
cell-line exosomes (26).
In this current report, therefore, we present an isolation
of exosomes isolated from blood plasma or urine speci-
mens using a SEC approach followed by an analysis
of enriched vesicle isolates by SOMAscan†. In the first
instance, using healthy donors, we compare the quality
of vesicle isolates generated from plasma and urine, and
demonstrate the successful identification of hundreds
of proteins; some providing a clear distinction between
vesicles of blood and urinary compartments. We also
undertook a small-scale study with specimens provided
by patients with metastatic prostate cancer using these
workflows. We conclude that the combination of SEC
with SOMAscan† assay can provide a means for proteo-
mics comparisons in a clinical setting and can potentially
identify vesicular proteins of blood or urine origin indi-
cative of treatment failure and progressive disease in
prostate cancer.
Experimental procedures
Blood and urine donors
Biofluid samples were collected from healthy donors under
informed consent and with ethical approval from Cardiff
University, School of Medicine Research Ethics Commit-
tee, under the reference number 14/55. All patient biofluid
samples were ethically obtained from consenting patients
with metastatic prostate cancer through a bespoke
specimen collection arranged through the Wales Cancer
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Bank. Sample collection was open for a period of around
6 months. Specimens were obtained from 2 clinical
scenarios; first, from men presenting with metastatic
prostate cancer prior to receiving any therapeutic inter-
ventions (annotated herein as Arm A), and second, from
men having failed all therapeutics, bearing progressive
disease (annotated as Arm B).
Urine sample collection
Up to 250-ml volume was collected into sterile containers
(Millipore, Watford, UK). Samples were not the first-
morning urine and were processed within 2 h of collection,
as follows. Urine was centrifuged at 400g (7 min, 208C)
to remove cells and subsequently at 2,000g (15 min, 48C)
to remove cellular debris. The urine fraction was collected
and 0.22-mm vacuum filtered to remove any remaining
large debris (Millipore). Urine was then stored at 808C
until processing for vesicle isolation. This was performed
B4 weeks post collection.
Plasma sample collection
Approximately 9 ml of blood was collected in K3 EDTA
tubes (Greiner Bio-One Ltd, Stonehouse, UK) and
the tubes inverted gently once in order to limit platelet
activation. With minimal agitation, blood samples were
centrifuged at 400g (7 min, 208C). The plasma layer was
then collected and centrifuged at 6,000g (fixed angle
rotor, 10 min, 208C). Platelet-free plasma was then syringe
filtered (0.22 mm) and stored (1.6-ml aliquots) at 808C
until processing for vesicle isolation. This was performed
B4 weeks post collection.
Vesicle isolation from plasma
Sepharose CL-2B (GE Healthcare Life Sciences, Little
Chalfont, UK) was diluted 1:1 with 0.1-mm filtered
phosphate-buffered saline (PBS) containing 1.8-mg/ml
ethylenediaminetetraacetic acid (EDTA) (Lonza and Sigma
Aldrich) and poured into long 30-cm glass columns
(12-ml bed volume; Bio-Rad Laboratories Ltd, Hemel
Hempstead, UK) (Fig. 1a). The columns were washed
with 30-ml mobile phase buffer (0.1-mm filtered 1.8-mg/ml
EDTA in PBS) and stored overnight at 48C. A volume of
1.5 ml of plasma was then thawed at ambient temperature
and after mixing, applied to the column and the first
3500-ml fractions collected. Without allowing the col-
umn to dry out, mobile phase buffer was added serially in
steps of 500 ml, and corresponding 500-ml fractions were
collected achieving up to 30 fractions in total. The protein
and particle content of each fraction was determined
by NanoDropTM (measuring absorbance at 280 nm, in
duplicates) and NanoSightTM, respectively. Fractions to be
processed and analysed were selected on the basis of the
first protein peak (by NanoDrop-protein measurements),
as explained in detail in the Results section. Those selected
fractions were pooled and washed with PBS and centri-
fuged at 200,000g for 2 h at 48C to pellet vesicles (using:
Quick Seal tubes; TLA-110 fixed angle rotor; OptimaTM
Max-XP ultracentrifuge; Beckman Coulter, High Wycombe,
UK). The supernatant was discarded and the pellet
resuspended in 40 ml of PBS and stored at 808C.
Vesicle isolation from urine
Similarly, Sepharose CL-2B was prepared as for the
plasma; however, the column itself was a 2.5-ml plastic
syringe barrel (plunger removed) with glass wool plugging
the bottom preventing the Sepharose leaking through.
The bed volume was 2.8 ml and was washed through with
6 ml of mobile phase buffer (Fig. 1b) and left overnight
at 48C to settle. Up to 260 ml of urine was thawed at 378C
in a water bath and, after mixing, it was subjected to
an additional centrifugation at 400g (7 min, 208C) and
0.22-mm vacuum filtration to remove any sediment. The
urine was then ultracentrifuged at 200,000g for 2 h at
48C (using: QuickSeal tubes; 70 Ti Fixed angle rotor;
Optima LE80 K Ultracentrifuge; Beckman Coulter). The
supernatant was discarded and the pellets resuspended in
a total volume of 500-ml PBS. The resuspended urinary
pellet was then loaded onto the column. The mobile phase
buffer was serially added in 165-ml steps, and correspond-
ing fractions of 165 ml were collected for a total of up to
30 fractions. Protein and particle content of each fraction
was determined and selected fractions pooled and vesicles
pelleted as above.
Nanoparticle tracking analysis (by NanoSightTM)
Vesicles/particles present in the fractions and final pellets
were diluted in particle-free water (Fresenius Kabi, Run-
corn, UK) to concentrations up to 2109 particles/ml
within the linear range of the instrument, and analysis was
performed on a NanoSightTM LM10 system as previously
described (27) but configured with a temperature-
controlled LM14 laser module with a 488-nm laser and a
high-sensitivity sCMOS camera system (OrcaFlash2.8,
Hammamatsu C11440) and a syringe-pump system
(Malvern Instruments, Malvern, UK). The analysis was
performed as described by Webber and Clayton (27), with
some modifications. Three videos of 30 s were taken under
controlled fluid flow with a pump speed set to 80 and
temperature set to 258C. Videos were analysed using the
batch analysis tool of NTA 2.3 software (version 2.3 build
2.3.5.0033.7-Beta7), where minimum particle size, track
length and blur were set as ‘‘automatic.’’ The area under
the histogram for each triplicate measurement was aver-
aged and used as a particle concentration measurement.
Microplate-based assay for vesicle surface markers
Immunostaining was performed as previously described
(26). Briefly, fractions were bound to protein-binding
microtitre ELISA plates (Greiner Bio-One, Stonehouse,
UK) at a dilution of 1:4. After overnight coupling and
blocking (with 1% (w/v) BSA in PBS for 2 h at room
temperature (RT)), the bound material was labelled with
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Fig. 1. Flowchart for the isolation of plasma- and urine-derived vesicles. Blood was collected into EDTA vacutainers and pre-cleared of cells,
filtered and frozen at 808C in 1.5-ml aliquots. The plasma was subsequently thawed and vortexed prior to applying to the home-made
12-cm bed volume 30-cm long Sepharose CL-2B size-exclusion column. PBS EDTAwas used as the mobile phase buffer and up to 30500 ml
fractions were collected (a). Urine was collected into 250-ml Stericups and pre-cleared of cells, filtered and frozen at 808C in aliquots up
to 50 ml. Upon thawing, the urine was vortexed and centrifuged and filtered a second time to eliminate sediment, and ultracentrifuged for
2 h, 48C, 200,000g. The subsequent pellet was resupended in 500 ml PBS and applied to a small 3-cm volume column made in a 2.5-ml
syringe. An 18-gauge needle was attached to the bottom of the syringe to guide the sample accurately into 500-ml microcentrifuge tubes in up
to 30165 ml fractions (b). For both plasma and urine, each fraction was subject to analysis by ELISA-like assays, protein measurement,
NTA, and when possible also by western blot. Alternatively, selected vesicle-rich fractions were pooled and concentrated/washed
(200,000g, 2 h, 48C). The pellet was resuspended in a small volume of PBS, and protein and particle concentrations determined and stored
at 808C. Prior to SOMAscan† analysis, occasional samples were assessed by cryo-electron microscopy.
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primary antibodies including CD9, ApoB, THP (Tamm
Horsfall protein) (at concentrations of 1 mg/ml) or HSA
(human serum albumin) (at 250 ng/ml) (R&D Systems)
all for 2 h at RT on a plate shaker. After 3 washes, goat
antimouse-biotinylated antibody (Perkin Elmer) diluted
1:2,500 was added for 1.5 h. After 3 washes, Europium-
conjugated streptavidin (Perkin Elmer) was added for
45 min. Finally after 6 washes, specific signal was measured
by time-resolved fluorometry using a Wallac Victor-II
multilabel plate reader (PerkinElmer Life). The method is
referred to as an ‘‘ELISA-like’’ assay in the text.
Electrophoresis and immunoblotting
Chromatographic fractions were boiled in sodium dodecyl
sulphate (SDS) sample buffer containing 20-mM 1,4
Dithiothreitol (DTT) as previously described (26,28).
Membranes were probed using antibodies against proteins
including TSG101 (clone C-2), ALIX (clone G-10),
LAMP2 (clone H4-B4) (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) or HSA (clone 188835) (R&D
systems, Minneapolis, MA) at 14 mg/ml in PBS-Tween
20 (0.05%) and detected using antimouse-HRP conjugate
(Santa Cruz) and super-signal picoWest luminescence
reagent (Thermo Fisher).
Cryo-electron microscopy
We performed cryo-electron microscopy (cryo-EM) to
examine the presence of vesicle structures in selected,
pooled column eluates. Around 5 ml of the specimen was
directly adsorbed onto glow-discharged holey carbon
grids (QUANTIFOIL, Germany). Grids were blotted at
95% humidity and rapidly plunged into liquid ethane
with the aid of VITROBOT (Maastricht Instruments BV,
The Netherlands). Vitrified samples were imaged at liquid
nitrogen temperature using a JEM-2200FS/CR transmis-
sion cryo-electron microscope (JEOL, Japan), equipped
with a field emission gun and operated at an acceleration
voltage of 200 kV.
Preparation of samples for the SOMAscan† array
The SOMAscan† multiplex assay consists of 1,129
individual affinity molecules called SOMAmer† (slow
off-rate modified DNA aptamer) reagents, each with very
high affinity to their protein targets (25,29). Exosomes
were prepared for the SOMAscan† assay by diluting
them to 200 mg/ml in a buffer consisting of 1SomaLogic
SB17, 1% NP-40 and 0.5% (w/v) sodium deoxycholate. The
diluted samples were incubated for 15 min on a rotisserie at
378C. This incubation is followed by a centrifugation step
at 14,000g for 5 min and the supernatant is recovered. A
volume of 72 mL of SomaLogic Plasma Diluent is mixed
with 12 mL SomaLogic Assay buffer and 36 ml of the above-
processed exosome preparation (material recovered
after centrifugation). This procedure results in a final
protein concentration of 60 mg/ml. The final sample is
incubated with a pool of 1,129 SOMAmer† reagents for
equilibration binding for 210 min at 288C. Two sequential
bead-based immobilization and washing steps were then
used to eliminate unbound or non-specifically bound
proteins and the unbound SOMAmer† reagents, leaving
only protein target-bound SOMAmer† reagents. These
remaining SOMAmer† reagents were isolated, and each
reagent was quantified simultaneously on a custom Agilent
hybridization array. The number of each SOMAmer†
measured is quantitatively proportional to the protein
concentration in the original sample.
Data handling, presentation and bioinformatics
analysis
The RFU (relative fluorescence unit) output from the
array was subjected to background subtraction. For both
the plasma- and urine-derived exosomes, this involved
utilizing the data collected from a 16-point titration, using
healthy donor specimens. The backgrounds/baselines were
established using SomaLogics’ method for calculating
background, which examines the RFU values for the 5
lowest dilutions in the titration. ‘‘The %CV is computed for
the RFU measurements of the 2 lowest dilutions, followed
by that for the 3, 4 and 5 lowest dilutions. A baseline is
defined by the median RFU for that set of points with
the lowest %CV below a threshold of 15%. If no set of
points had a %CV below the threshold, the baseline is
set to zero.’’
After background subtraction had been performed, the
significant differences between plasma- and urine-derived
exosomes was assessed using row-by-row t test, and
additional correction for multiple testing was applied
using the BenjaminiHochberg (BH) procedure. Negative
values were made zero and proteins with zeros for both
means were eliminated from further analysis. Hierarchical
clustering was performed using Euclidean distance with
the complete linkage method. All graphs in Fig. 5 were
generated using R in RStudio version 0.99.483 for
Windows (RStudio, Inc., Boston, MA).
If protein identifications are represented as genes, in
the Gene Ontology analysis, any SOMAmer† which
report with 2 or more genes because they may recognize
a protein complex, all gene names were included. The
protein identifications which demonstrated significant
differences and a minimum of a 1.5-fold change were
analysed using FunRich version 2.1.2 for Windows (30)
to examine the subcellular location of the proteins. This
was performed using the UniProt Human Taxon (13/10/
2015) as a background and the Entrez gene accession
numbers as the method of gene annotation for each of the
SOMAmer†’s of interest. The most significantly enriched
subcellular locations are depicted in Figs. 6c and 7c.
All other graphs were generated using GraphPad
Prism version 5.01 for Windows (GraphPad Software,
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San Diego, CA), which was also used to calculate sta-
tistics for comparing groups (data presented in Fig. 4),
based on 1-way ANOVA, with Tukey’s honest significance
post-test, where *pB0.05, **pB0.01, ***pB0.001 and
****B0.0001.
Results
Isolation of vesicles from plasma specimens
Several methods for isolating exosome vesicles from
plasma were tested including ultracentrifugation, Opti-
prepTM gradient ultracentrifugation, tangential flow
filtration, dialysis and various combinations of these. We
found that these methods poorly separated the vesicles
from the bulk of non-exosomal protein. Some methods
were also very time consuming, taking up to 2 days to
perform and thus making them impractical for processing
potentially large numbers of clinical samples (data not
shown). We subsequently explored other options, includ-
ing the simple size-exclusion chromatographic approach
described recently by Bo¨ing et al. (23), based on packing
a 10-ml syringe barrel with 12-ml Sepharose CL-2B.
This was successful in the separation of most of the
vesicles from the majority of the blood proteins and was
performed in a comparable manner to a commercially
available column (Midi Column, Cell Guidance Systems,
Cambridge), as we previously described (31). However,
the use of a longer column (30-cm long) with a smaller
diameter (around 0.5 cm), as shown in Fig. 1a, with the
same 12-ml bed volume of Sepharose CL-2B, we were able
to see an improvement in resolution with slightly better
separation of vesicles from albumin and other proteins
(data not shown).
Using our variation on this method, depicted in
Fig. 1a, pre-cleared healthy donor plasma was defrosted
at RT prior to loading onto a pre-prepared column. To
inhibit coagulation, 1.8 mg/ml K3EDTA was added to
PBS as the mobile phase buffer. Up to 30 fractions of
500ml were collected, taking 12 h to complete. A proportion
of each fraction was assayed for protein (by absorbance
at 280 nm, using a NanoDropTM device) and assessed for
nanoparticles using the NanoSightTM platform (27). Over
95% of the protein contained within the fraction series
was present between fractions 15 and 26 (Fig. 2a). The
particle-to-protein ratio was used as a means of estimat-
ing vesicle purity as previously described (27), and this
showed the purest eluates encompassed fractions 1018.
By staining a proportion of each fraction applied to a
protein-binding microtitre plate, we were able to track the
presence of typical exosome-vesicle-associated proteins,
revealing a peak between fractions 10 and 18 containing
the tetraspanin proteins CD9 and CD81 (Fig. 2b, left
axis). We also saw some staining, albeit weaker for ApoB
in the same fractions. The signal for HSA (Fig. 2b, right
axis) began to increase strongly after fraction 15, corre-
sponding to the increase in total protein, but this signal
continued to rise beyond fraction 30. On 3 occasions, we
attempted to demonstrate exosome-associated markers
along the SEC-derived fraction series by western blotting,
but each time the protein load in the wells was simply
overwhelming and prevented us from generating compar-
able gels as seen for the urine samples (to follow).
Based on the above, selecting fractions 1015 ensures
maximal capture of vesicle markers and high particle-to-
protein ratios. Some signal for HSA was still apparent
within these fractions and so HSA may not have been
removed completely by selecting fractions 1015; however,
this selection minimized its inclusion while retaining as
much vesicle marker as possible. At this time, however, it is
not clear whether the presence of ApoB in the exosome-
rich fractions is due to the co-isolation of lipoproteins
or whether the ApoB may be a constituent part of the
exosomes as previously documented (32,33).
The selected fractions were subsequently subjected to a
centrifugation step to further wash away non-vesicular
proteins and concentrate the sample. Cryo-electron mi-
croscopy of the resuspended pellet revealed populations
of lipid-bounded, spherical vesicles of typical exosomal
size (100 nm). These structures were not uniform in
appearance, with some heterogeneity revealing occasional
vesicles with the appearance of being within other vesicles
(Fig. 2c). This phenomenon is not unusual and has been
observed in other studies (34,35). There are, however,
other rare electron dense structures present in some
microscopic fields, possibly representing lipoproteins (36)
or debris of unknown nature (Fig. 2c, arrows). Overall,
however, analysis of particulate material in the final pre-
parations by NanoSightTM reveals a single monodisperse
peak consistent with a preparation of small vesicles with
exosome characteristics (Fig. 2d).
Isolation of vesicles from urine specimens
We adapted the above isolation protocol in order to
accommodate the large volume of urine collected for
the study, as summarized (Fig. 1b). Pre-cleared urine was
concentrated down to a pellet, and resuspended in 500-ml
PBS and loaded onto a pre-prepared mini Sepharose
column (a 2-ml syringe barrel, holding 1-ml Sepharose
CL2B). Up to 30 fractions of 165 ml were collected taking
1015 min to complete, and the protein and particle con-
centrations were determined. The fractions were analysed
as above by the same microtitre plate assay and also by
western blotting; staining for markers as indicated.
Uncropped blots are shown (Supplementary Fig. 1).
The western blots reveal a clear separation of the HSA-
containing fractions from those containing some of the
classical exosome-associated markers, TSG101, ALIX
and LAMP2 (Fig. 3a). These exosome marker positive
fractions (612) also exhibited the highest particle-
to-protein ratios (Fig. 3b) and had the highest levels of
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CD9 staining (Fig. 3c). One of the most abundant
urinary proteins is the THP, also known as uromodulin,
which is present as a glucose-6-phosphate isomerase
(GPI)-anchored monomeric membrane protein of around
68 kDa but is also found as huge aggregates in urine (37).
THP, however, was not separated from the exosome-
containing fractions by the ultracentrifugation/SEC method
(Fig. 3c), and in fact showed a very broad elution profile
consistent with a wide range of molecular weights. Its
first appearance, in fraction 5, coincides with the first
appearance of exosome-related proteins, and this suggests
potentially some degree of exosome association.
Fractions 512 that have high particle-to-protein ratio,
high exosome marker and low HSA were pooled and
Fig. 2. Analysis of plasma fractionated by size-exclusion chromatography. Pre-cleared plasma was subject to separation on a 12-cm
long Sepharose CL2B size-exclusion column, and 30 serial 500-ml fractions were collected and analysed. The protein concentration was
estimated by NanoDropTM (absorbance at 280 nm), and the particle concentration was measured by nanoparticle tracking analysis
(NanoSightTM). Individual fractions where NanoSightTM analysis was not performed are indicated (with an X). The ratio of particles
to protein (particles/mg) was calculated and plotted (left axis: blue bars) with total protein on the right axis (red line) (a). A proportion of
the same fraction series was immobilized onto high-protein-binding microplate strips and allowed to couple overnight. After blocking,
wells were stained with primary antibodies against CD9, CD81, ApoB or HSA, and binding detected using a time-resolved fluorometric
readout (arbitrary TRF units shown) (b). Selected fractions (F10 to F15), identified as vesicle rich but protein low by the aforementioned
assays, were pooled and concentrated by ultracentrifugation. After re-suspending the pellet, a proportion was examined by cryo-EM
(scale bar100 nm), and representative fields are shown (c). A proportion was also analysed by nanoparticle tracking to examine the
size distribution of particles in the final sample, and the histogram mean and mode is shown (based on triplicate measurements) (d).
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Fig. 3. Analysis of urine fractionated by ultracentrifugation and size-exclusion chromatography. Urine was concentrated by pelleting
(200,000g, 2 h, 48C) and after re-suspending, the material was fractionated using a Sepharose CL-2B size-exclusion chromatography
column. Thirty fractions were collected. Equal volumes of fraction 4 to fraction 25 were examined by western blotting; staining for the
endo/lysosomal-related proteins including TSG101, ALIX, LAMP2 or for serum albumin (HSA). For this number of samples, 2 gels
were required, and the position of the divide between the gels is indicated by a dotted line (a). In addition, the protein and particle
concentrations were determined (for the latter, those that were not measured are denoted by an X). The particle-to-protein ratio was
calculated and is plotted (blue bars) together with total protein estimation (red line) (b). A proportion of the same fraction series was
immobilized onto high-protein-binding microplate strips and allowed to couple overnight. After blocking, wells were stained with
primary antibodies against CD9, THP (uromodulin), HSA or isotype control, and binding detected using a time-resolved fluorometric
readout (arbitrary TRF units shown) (c). Selected fractions (F5 to F12), identified as vesicle rich but protein low by the aforementioned
assays, were pooled and concentrated by ultracentrifugation. After re-suspending the pellet, a proportion was examined by cryo-EM
(scale bar100 nm), and representative fields are shown (d). A proportion was also analysed by nanoparticle tracking to examine the
size distribution of particles in the final sample, and the histogram mean and mode is shown (based on triplicate measurements) (e).
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subjected to an ultracentrifugation wash and concentra-
tion step. Observations by cryo-EM (Fig. 3d) revealed
membrane-bounded vesicular structures of sizes consis-
tent with the exosome vesicles similar to those isolated
from plasma. There were few microscopic fields containing
the aforementioned dense structures that would not be
considered as vesicles (Fig. 3d, arrows). Analysis of the
final preparation by NanoSightTM shows, overall, a pre-
dominant peak of typical exosome size (mode of 73 nm),
with perhaps some occasional particulates at larger sizes
(Fig. 3e).
Assessing vesicle yield, purity and variation across
healthy donors
We performed the above workflows for plasma (n10)
and urinary (n13) specimens donated from healthy male
volunteers in order to assess the amount of vesicles that we
could isolate and also to examine the variation we might
expect using this approach. Analysing the post-column
eluates using all of the aforementioned assays would
consume too much sample, however, leaving too little for
subsequent proteomics analyses, and hence we could not
use this approach for selecting relevant vesicle-containing
fractions. On occasion, some columns ran 1 or 2 fractions
fast/slow and, hence, we decided against relying on
fraction number as an absolute means of fraction selec-
tion. Instead, we based fraction selection on the protein
assessment. Regardless of columns dimensions (plasma
or urine columns), we consistently saw a small ‘‘hump’’ in
the protein levels corresponding to the vesicle-containing
factions. This is nicely shown Fig. 3b (red line, fractions
510). Our selections were, therefore, based on the posi-
tion of this ‘‘hump,’’ and we pooled the fractions spanned
by this protein peak.
The pooled fractions were pelleted and the final
product analysed for protein and particle concentration,
by NanoDropTM and NanoSightTM analysis, respectively
(Fig. 4). As a source of vesicles, plasma gave significantly
more (pB0.001) material in terms of particles (around
45-fold) and protein (around 137-fold) (Fig. 4a) per ml of
input volume compared to urine. The urinary volume
obtained from individuals was variable, but at least 60 ml
was processed for each donor, while a consistent 1.5 ml
was achieved across the individuals for plasma. When
making comparisons irrespective of input volume, the total
isolated particle (urine5.91101195.761011 versus
plasma2.88101191.981011, p0.05) and protein
(urine44.82942.47 mg versus plasma73.92941.04 mg,
p0.5) quantities were approximately comparable, with
greater variance in the urine samples partly explained
by this input volume issue (Fig. 4b). We also examined
the particle-to-protein ratio across these specimens, as a
simple means of estimating vesicle purity. The average of
urine-derived vesicle preparations exhibited a 3.36-fold
higher ratio than plasma vesicles, indicating that the final
preparations generated from urine were purer overall
than those taken from plasma (pB0.001). In fact, the
urinary particle-to-protein ratios were approaching the
purity of samples generated from cell culture sources (27).
When normalizing the specimen for subsequent proteomics
analysis, we suggest that a greater proportion of the urine
sample would constitute vesicles compared to plasma,
and given the complexity of the plasma proteome, this is
not entirely unexpected.
Protein profiling of vesicle isolates
We next tested the compatibility of our SEC-derived
vesicle isolates with a well-established liquid chromato-
graphy/mass-spectrometric platform (LC-MALDI) as we
previously described for cell-culture-derived exosomes
(28). We did this with plasma and not urine, as this was
the more challenging specimen type, in terms of vesicle
purity. Using healthy donor plasma as the vesicle source,
we generated a list of only 21 proteins (reporting with ]2
peptides), compared to over 300 proteins with cell-
culture-derived vesicles (28), and these represented the usual
high abundance blood proteins, and was devoid of iden-
tifications we would ascribe to vesicles (Supplementary
Table 1). While performing SEC followed by ultracentrifu-
gation, 97% of protein were eliminated. Nevertheless, the
sample remained too replete with these high abundance
proteins to generate useful data by this MS approach.
We therefore considered using an alternative protein-
profiling technology, based on a protein array platform
as this successfully generated reliable, semi-quantitative
data with cultured cancer-cell-derived exosomes as a
specimen (26). We expected that contaminating protein
in the isolates would not confound the identification of
lower abundant proteins of interest with the array
method. We also wanted to examine the reproducibility
of our vesicle isolation workflow and how variance here
may impact the proteomics data quality. For this experi-
ment, therefore, we pooled healthy donor plasma or urine,
and each pool was separated by 3 independent SEC
columns. Vesicle isolates were shipped to SomaLogicTM
(Boulder, CO) for analysis. Specimens were examined
on the SOMAscan† v3.0 array at a concentration of
60 mg/ml protein. This dose was predetermined by a titra-
tion experiment in which most of the target proteins
within the array menu reported with signal above the
background at this dose.
The data are summarized in Fig. 5 and appended in
full as Supplementary Table 2. Fig. 5 shows the positive
identification of 1,035 proteins following background
correction and good reproducibility across the replicates.
For urine, the median %CV across the identified proteins
was only 4.1%, with over 87% of these below 10% CV.
This was slightly less consistent for plasma, with a median
of 7.7% CV and 68% below 10%. Some of the identifica-
tions reported with a low signal, for example, with an
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RFUB200 units; approaching the lower limits of detec-
tion of the array. Some studies have utilized an arbitrary
cut-off value of 200 RFU, to gain greater confidence of a
positive identification, at the expense of losing some poten-
tially relevant results (26). Because of the background
correction performed here, however, we chose to present
the entire data without such a cut-off and cautiously con-
sider these low signal proteins as low abundance positives.
Fig. 4. Vesicle yields and purity. Urine or plasma specimens
were collected from healthy male donors and processed by the
aforementioned methods to generate a preparation of vesicles.
For each run of plasma (n10 donors), a total volume of 1.5 ml
was processed. The urine donated (n13), however, was more
variable, ranging from 60 to 250 ml. The final vesicle prepara-
tions were measured for protein and particles and the data
plotted as dot-plots where each symbol is a different donor, and
the mean and standard error is shown. In (a), the data are
corrected for the initial starting volume (p50.001), indicating
that plasma provides greater quantity of particles and protein
compared to urine. In (b), data show the total material achieved
in the vesicle isolates irrespective of input volume. The particle-
to-protein ratio as an estimation of sample purity is depicted in
(c) (p50.001).
Fig. 5. Proteomics analysis of vesicles derived from healthy
donor urine and plasma. A pool of healthy donor urine or
plasma was used as a source of biofluid and for each, 3 separate
isolation procedures were undertaken to generate technical
replicates. To help evaluate the reproducibility of the prepara-
tion methods, the specimens were subject to protein profiling
using the SOMAscan
†
protein array. A total of 1,035 proteins
was identified following background correction, and these are
represented by a scatter plot of the loge of the RFU values for
both exosome sources. The different coloured circles represent
the statistical significance of each protein as determined by row-
by-row t test (with BH correction), as indicated in parentheses
(a). Some examples of proteins more highly expressed in urine
(b) or plasma (c) are shown. A total of 392 proteins exhibited
comparable expression levels (p]0.05) in both urine- and
plasma-derived vesicles (d). (Bars show mean RFU values9SD
SD of triplicates, **p50.01, ***p50.001, ****p50.0001).
The full data set is available as Supplementary Table 2. Venn
diagram compares the urine results, with previously published
studies of healthy donor urinary exosomes, using mass spectro-
metry, showing the degree of identifications in agreement across
these data sets (e).
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We compared the relative levels of identified proteins in
urine and plasma vesicle isolates. There were significant
differences seen for 643 proteins, and the level of signifi-
cance is shown (as coloured symbols in Fig. 5a). We found,
for example, a total of 317 proteins at the significance level
of p50.01 that were more abundant in urine vesicles
compared to plasma vesicles. These included contactin 1
(14-fold higher), S100A9 (16-fold), testican 1 (28-fold),
integrin aVb5 (61-fold) and HSP90a/b (over 70-fold)
(shown in Fig. 5b). Although some proteins showed
infinite enrichment in urine compared to plasma (i.e.
presence versus absence), such as Hsp90 co-chaperone
Cdc37 (CDC37) or fibroblast growth factor 7 (FGF7),
most of these reported with very low RFU values, and
we are uncertain about the level of enrichment of these.
There were examples, however, of proteins of over 100-fold
more abundance in urine and reporting with high RFU
values indicating a strong detection signal, including
vacuolar protein sorting-associated protein VTA1 homo-
log (DRG-1) (over 1,600-fold), galectin-8 (almost 700-
fold), Ras-related C3 botulinum toxin substrate 1 (RAC1)
(315-fold) and others. Most of these have previous reports
pointing to vesicle association from searching Vesiclepedia
(19 Jan 2016) (5).
Similarly, there were 45 proteins that were more highly
expressed (p50.01) in plasma-derived vesicles, and,
as described above, the level of relative enrichment for
some was striking, including protein S (over 5,000-fold),
complement factor H (over 3,500-fold), fibrinogen (over
800-fold), a2-macroglobulin (over 700-fold), as well as
more modest levels of relative enrichment of hepatocyte
growth factor activator (HGF-A) (312-fold) and PSA
ACT (PSAantichymotrypsin complex) (2.3-fold) (Fig. 5c).
A handful of other proteins would also have shown enri-
chment in blood versus urinary isolates, such as platelet
factor-4 (PF-4) or plasma kallikrein; however, due to
the high variation in the triplicates for these particular
analytes, they reported high p values and are considered as
not confidently different (Supplementary Table 2). Many
within this list of 45 proteins would be consistent with the
carryover of blood proteins into our vesicle isolates.
Having said this, we may particularly have expected high
albumin levels for plasma-derived vesicles, as this protein
accounts for around 55% of total blood proteins. The
signal strength for albumin was surprisingly low and
similar to the urine-vesicle level; presenting good evidence
for a major removal of albumin from the samples (Fig. 5d).
Many membrane-associated proteins, however, are found
in this list, for example, integrin aIIb,b3 complex (190-fold
more in plasma versus urine), neurogenic locus notch
homolog protein 1 (Notch1) (46-fold), and high-affinity
immunoglobulin gamma Fc receptor-I (36-fold). The data
likely, therefore, represent membrane vesicles and blood
proteins, and point to the advantage of the protein-array
method for identifying membrane/vesicular proteins even
in the presence of high signals for some of the aforemen-
tioned blood-related components.
There were 392 proteins in total that did not reach
significant differences when comparing plasma and urinary
isolates. These reported with broadly comparable RFU
levels between the biofluid sources including insulin-like
growth factor-1 (IGF-1), calpastatin, cathepsin-D, and
the membrane proteins CD39 and CD97 (shown in
Fig. 5d), vascular cell adhesion protein 1 (VCAM-1),
Wnt inhibitory factor 1 (WIF-1), CD30 and many others.
These are again examples of previously reported vesicle-
related proteins, and suggest vesicles in plasma and urine
show many common features (5).
We examined the Vesiclepedia database to search for
previous exosome-proteomics studies in relation to healthy
donor urine. We chose not to do this with respect to
plasma, given the aforementioned issues of sample purity.
For urine, we identified 3 such studies with good numbers
of listed proteins. Specifically, a study by Pisitkun et al.
(13) (Vesiclepedia ID: 13) reported 614 identifications;
Gonzales et al. (38) (VP-ID: 63) reported 1,059 identi-
fications; and Wang et al. (39) (VP-ID: 437) reported
3,082 proteins, presented as a Venn diagram (Fig. 5e).
There were 79 proteins that were common across these and
our presented study, although this amounted to only
2% overlap of all the considered proteins. These common
proteins included several enzymatic elements related to
metabolic activity, malate dehydrogenase-1 (MDH1),
GPI, and phosphogluconate dehydrogenase (PGD). There
were identifications associated with protease regulation,
serpin peptidase inhibitor (SERPING1), inter-alpha-
trypsin inhibitor (ITIH4), membrane-related proteins;
phosphatidylethanolamine-binding protein 1(PEBP1) and
clusterin (CLU) in addition to markers of endocytic
compartments (vesicle (multivesicular body) trafficking 1).
These common elements lacked the expected exosome
markers like tetraspanins, TSG101, Alix or others, as these
are not currently included within the SOMAscan† menu.
They are, however, shown as present in the urine-vesicle
specimens by western blotting and other approaches
(Fig. 3). Our study shows 350 proteins overlap with the
Wang study, whereas the same comparison of Pisitkun or
Gonzalez with Wang shows 559 and 870 proteins over-
lapping, respectively. This, we believe, is a reflection of the
very different technologies used here that has identified
669 proteins not found by these other studies.
Analysis of vesicles from men with prostate cancer
Having established that the vesicle isolation method and
SOMAscan† platform were a suitable combination for
analysing plasma and urine-vesicle isolates, we went on
to analyse clinical samples from patients with metastatic
prostate cancer. A bespoke sample collection was initiated,
aiming to collect plasma and urine from prostate cancer
patients who were either newly diagnosed with multiple
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metastasis and had received no therapeutic intervention
(Arm A) or from men who had failed first- and second-line
treatments and had hormone-refractive progressive dis-
ease (Arm B). Such a comparison would highlight markers
indicative of treatment failure, which would be clinically
useful if obtained in a non-invasive manner. Although we
had intended to collect from 12 to 20 individuals in each
group, this was not possible in the timeframe available
for the study. In addition, some urine specimens were of
low volume or contained blood and did not provide
sufficient material for proteomics analysis; and hence we
were able to generate successful vesicle preparations from
a total of 11 plasma and only 5 urinary donations.
For plasma vesicles, comparison of Arm A with Arm B
disappointingly revealed that none of the 990 identified
proteins were significantly different across these groups,
when using the BH correction. Even when applying
an arbitrary cut-off, in order to remove any noise in the
data from identifications reporting with an RFUB200,
only 2 proteins became significant with the BH procedure
namely; complement C 1r and 14-3-3 (pB0.001). This
filtering had no impact on BH-corrected statistics for the
urinary samples. This is an issue related to the variation
from genuine biological replicates, and too few specimens.
Although we concede this as a serious limitation of
the current study, we wanted to find some proteins that
might serve to discriminate these patient groups. We
therefore decided to use a clustering approach, removing
the extreme outliers and only comparing the more tightly
clustered specimens therefore. This allowed for an Aversus
B comparison with 3 donors in each arm (Fig. 6a). This
comparison highlighted that 102 proteins exhibited
significant differences (p50.05, without BH correction)
and, of these, 57 proteins showed a]91.5-fold difference
between arms A and B (37 elevated and 20 decreased)
(Fig. 6b and Supplementary Table 3A). Proteins, including
CC motif chemokine-15 (CCL15) and cathepsin-D,
were essentially not detected in patients in Arm A and
were only apparent in progressive disease. Other elements,
including adiponectin, intercellular adhesion molecule-2
(ICAM-2), transforming growth factor beta-2 (TGFb2)
and bone morphogenic protein-1 (BMP1) are examples of
those elevated in progressive disease. In contrast, the
prolactin receptor, killer cell immunoglobulin-like receptor
2DL4 (KIR2DL4), interleukin-17 receptor-C (IL-17RC),
cadherin-2 and others were lost on disease progression,
together with a reduction in natural cytotoxicity triggering
receptor-1 (NCR1), CD200R1, CC motif chemokine 27
(CCL27) and several others implicated in inflammation,
immune function, adhesion and other processes. Some
of the proteins in the list might normally be considered
as high abundance blood-associated proteins like comple-
ment C1q, fibronectin and protein S. It is important to
consider that some of these identifications may reflect non-
vesicular elements in the preparations. Functional enrich-
ment analysis, based on the 57 proteins, was performed
using the FunRich tool (30) and revealed significant
associations with terms including ‘‘platelet alpha granule
lumen,’’ ‘‘extracellular space,’’ ‘‘blood microparticles,’’
‘‘extracellular region,’’ and others that may be consistent
overall with a vesicle analysis (Fig. 6c).
Similarly, this approach was also taken with a limited
number of available urinary vesicle isolates. Clustering
was used to select 2 patients for each arm for subsequent
analysis (Fig. 7a), which gave 62 proteins with significant
differences across the 2 groups (p50.05) and 41 showed
a ]91.5-fold difference (Fig. 7b). Of those, several
growth factors/cytokines were evidently increased includ-
ing FGF19, insulin-like growth factor-binding proteins
2 and 5 (IGFBP2 and IGFBP5), CC motif chemokine-
16 (CCL16) and CD226 antigen in progressive disease.
MHC class I polypeptide-related sequence-A (MICA),
von Willebrand factor and A disintegrin and metallopro-
teinase with thrombospondin motifs 1 (ADAMTS1) were
reduced upon progressive disease. There was an absence
of high abundance blood proteins, such as complement
factors from the list, perhaps as expected; however, serum
albumin was present and apparently elevated in the
urine vesicles during progression. Functional enrichment
analysis of the list again highlighted terms including
‘‘extracellular space,’’ ‘‘platelet alpha granule lumen’’ and
‘‘blood microparticle,’’ as we found for plasma vesicles,
and the overall ontology information was similar.
Discussion
In this study, we present a practical means for the isolation
and proteomic analysis of vesicles in blood plasma and
in urinary specimens. Although the schemes we have
derived require some sample-handling time, it is never-
theless an approach amenable to handling tens of samples
in a clinical study while also providing a final vesicle-
rich preparation of good purity and reproducible yields.
The combination of the sample-processing steps, together
with a protein-array technology, generates a data set that
would not otherwise be available from more traditional,
mass-spectrometric-based methods. We suggest that our
study presents a platform that can be built upon in general
and hopefully applied to diverse clinical settings.
Generating very pure vesicles isolated from biofluids
has remained a major problem for researchers searching
for vesicle-associated disease biomarkers. Arguably, this
issue may be less of a concern when examining vesicular
RNA where material not encapsulated within the vesicles
can be enzymatically cleared with RNAse (6). With highly
proteinaceous biofluids like plasma, however, the removal
of a limited repertoire of very highly abundant proteins has
frustrated the progress of vesicle proteomics somewhat,
requiring some very long and labour-intensive protocols
to partially overcome this issue (21). As a preliminary
step to this work, we had also evaluated the ultracentrifu-
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gation of biofluids on gradients or cushions (40) and con-
cluded that the time required for each specimen was
very limiting in terms of sample throughput. Even with
OptiPrep as a separation medium, reportedly giving
superior resolution compared to sucrose gradients (41),
we found incomplete separation of vesicle-containing
fractions from blood proteins, particularly albumin, and
the fractions of exosomal density (1.21.2 g/L) retained the
pigment colour of bilirubin (data not shown). In contrast,
employing a SEC step as our principal mode of separating
vesicles from biofluid proteins provides a relatively effec-
tive method that can be performed in a reasonably short
timeframe. Other researchers have also utilized a chroma-
tographic approach to fractionate biofluids to good effect,
both in terms of plasma (42,43) and urine (44). With these
and, indeed, our protocol, there are a diverse range of
Fig. 6. Comparison of prostate cancer patient plasma-derived vesicles. Vesicle isolates were prepared from the plasma of metastatic
prostate cancer patients and assayed by SOMAscan
†
. Cluster analysis was performed (n11 patients), and 3 samples were selected for
further analysis from arms A and B; denoted by dashed line boxes. The sample identifiers are annotated with a letter ‘‘P’’ for plasma
and then either an ‘‘A’’ or ‘‘B’’ denoting study arm (a). Of 990 proteins identified by the assay, 102 showed significance (pB0.05)
between the 2 arms. Of these, 57 exhibited ]91.5-fold change difference in Arm B compared to Arm A (37 elevated and 20 reduced) (b).
Results of functional enrichment analysis to examine the subcellular location of the proteins are depicted where the grey line represents
log10 (p value) and black bars represent % gene coverage (c). The data set is shown in Supplementary Table 3A.
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choices and variables to be optimized in these workflows,
including different preclearing steps, different means of
sample concentration (ultracentrifugation, precipitation or
various concentration devices like Centricon-centrifugation
concentrators) (42,44), and indeed different resins and
column dimensions for chromatographic separation (31,43).
Fig. 7. Comparison of prostate cancer patient urine-derived vesicles. Vesicle isolates were prepared from the urine of metastatic prostate
cancer patients and assayed by SOMAscan
†
. Cluster analysis was performed (n5 patients), and 2 samples were selected for further
analysis from arms A and B, denoted by dashed line boxes. The sample identifiers are annotated with a letter ‘‘U’’ for urine and then
either an ‘‘A’’ or ‘‘B’’ denoting study arm (a). In this case, 993 proteins were identified in this 2 versus 2 comparison, of which 62 proteins
showed significance (pB0.05) between the 2 arms. Out of these, 41 proteins demonstrated 1]91.5-fold change difference in Arm B
compared to Arm A (33 elevated, 7 decreased) (b). Results of functional enrichment analysis to examine the subcellular location of the
proteins are depicted (c), where the grey line represents log10 (p value), and black bars represent % gene coverage. The data set is shown
in Supplementary Table 3B.
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Studies by these and other researchers continue to strive
towards the simplest and most-effective workflow for
isolating the purest possible vesicles from such complex
source material, yet it is likely that chromatographic
approaches are here to stay, given their simplicity and
relative efficacy in this regard.
The handling of urine specimens required prior con-
centration of vesicles prior to SEC, and we used ultra-
centrifugation for this step. This, together with filtering,
removes a proportion of non-vesicular material prior
to SEC-based clean-up, and this is therefore not a single-
step approach, as described by Bo¨ing et al. for platelet
concentrates (23), but is more comparable to the method
described by Lozano-Ramos et al. (44), who used a
centrifugation concentration step prior to SEC fractiona-
tion. For urine, the fractions of interest arising from
the column showed typical traits of exosomes, comprising
small membrane-bounded vesicles that were strongly
positive for surface tetraspanin proteins and positive for
endocytic markers TSG101, LAMP2 and Alix. These
preparations were of good purity and were sufficiently
devoid of protein load as to provide excellent samples for
western blotting, for example. Pooling selected fractions
was followed by a further ultracentrifuge wash/spin, giving
a final specimen of very good purity, according to our
previously published particle-to-protein assessment (27).
It is clear, however, that as one of the most abundant
urinary proteins, THP (TammHorsfall protein or uro-
modulin) was not removed from the vesicle-containing
fractions as this remained readily detected across a broad
range of vesicle-positive and vesicle-negative fractions.
Other steps, such as the salt-based precipitation of THP
(45) or the use of DTT (38), have been proposed by
other researchers as a means of THP reduction in urinary
vesicle specimens, and this seemed successful in the
Lozano-Ramos study (44). We chose not to adopt these
steps as high salt or DTT may interfere with the proteomics
array. Instead, we proceeded with a level of THP in these
vesicle isolates and have nevertheless generated a quality
proteome data set from the samples. When comparing
our data with some previous studies of urinary vesicle
protein profiling, we highlight the unique identification of
over 600 proteins, not previously identified. Most of the
SOMAscan† menu of 1,029 proteins therefore represents
proteins that were not detected by the more traditional
MS-based methods with this specimen type. This brings
a complementary technology to this topic that can high-
light elements which are difficult to reveal by the usual
methods, hopefully facilitating the discovery of new,
disease-relevant markers.
The fractions generated from plasma following the use
of long columns for SEC were effective at reducing the
vast majority of blood proteins from the sample, and
we estimate this to be 97% reduction. The relevant
fractions showed evidence of typical exosome vesicles by
cryo-EM together with positive tetraspanin expression.
There remained detectable, albeit low levels of albumin
in the vesicle-containing fractions and likely also a host of
other typical blood proteins. The proteomics data point to
components of the complement and clotting systems, for
example, certainly indicative of an imperfect purification
of vesicles, and many of these like D-dimer, fibronectin,
properdin reported with very high RFU values suggestive
of very high abundance in the specimen. In addition, the
final particle-to-protein ratios generated from plasma
also indicated a sample of inferior purity compared to
urine. Certainly, our failure to generate useful data based
on LCMS with such samples would point to the presence
of dominant/confounding blood proteins in these pre-
parations that mask the identification of more interesting,
low abundant and vesicle-related proteins. Working
with plasma for vesicle proteomics, therefore, remains a
challenge, and our presented sample-handling workflow
facilitates a major depletion of such contaminants but is
only a partial success, as it does not achieve elimination.
We have learned that tracking albumin as an example
blood protein may not give an entirely accurate account
of blood-protein carryover, and based on these data, we
would also include some of the aforementioned abundant
blood components, for example, D-dimer, to better assess
the impact of the clean-up steps employed. It is difficult,
however, to ascertain whether a protein element is a co-
isolated contaminant or if it is genuinely associated with
vesicles in the isolates. While we have tried to well qualify
the nature of the inputted material by an assortment
of assays including their chromatographic mobility, the
presence of certain markers, and imaging and sizing of
vesicles as advised by the recent ISEV-position paper (46),
absolute vesicle association remains ambiguous with
such complex biofluid samples. Further effort to tease
this out on a protein-by-protein basis would be needed
for the candidates of greatest interest and could be
achieved using a post-column affinity isolation method
or immunolabelling and electron microscopy.
As with many such studies, translating workflows
developed with healthy donor specimens to clinical speci-
mens proved challenging in the available timeframe for
the study. In particular, urine donations from meta-
static prostate cancer patients proved difficult to obtain,
with several unsuitable for subsequent processing due
to insufficient volume (that is, B60 ml) and/or due to the
presence of macroscopic haematuria. We are, therefore,
cautious about statements in relation to these clinical
specimens, as the study lacks sufficient power to make firm
conclusions. Nevertheless, the combination of isolation
method and protein array proved to be achievable and
generated identifications that potentially discriminate
newly diagnosed from progressive prostate cancer. In
plasma isolates, a number of elevated proteins known as
markers of prostate cancer or of disease progression were
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highlighted, including haptoglobin (47), adiponectin (48),
proprotein convertase subtilisin (49), cathepsin-S (50), the
spondin-related members (R-spondin-2 and spondon-1)
(51) and the invasion marker tissue-type plasminogen
activator (52). The loss of other proteins such as epithelial-
adhesive molecules, cadherins and proteins related to
immune function (CD200R1, KIR2DL4) would also be
consistent with worsening disease. Many others in the list
are not to our knowledge particularly related to prostate,
or cancer progression such as matrilin-2, or 4E-BP2, and
as such have cautious potential value as novel elements
related to progression. Similarly, urinary vesicles showed
some proteins with known associations with prostate
cancer including kininogen-1 (53) and insulin-like bind-
ing proteins (54), with again cautiously novel proteins
including Afamin, cardiotrophin-1, legumain and others
as elevated during progression.
In summary, we have developed practical methods
suitable for the enrichment of vesicles from plasma and
particularly for urinary specimens, based on combina-
tions of ultracentrifugation and chromatography. The
resulting vesicle-rich samples are purer when from urine
compared to plasma and are both of consistent quality
and of sufficient quantity for proteomics analysis. Analy-
sis using a multiplex protein-assay (SOMAscan†) pro-
vides a useful solution to the problem of co-isolated blood
proteins and generates a comprehensive profile of around
1,000 proteins present in the vesicle isolates. As a proof of
concept, we show the utility of this approach with clinical
specimens from men with metastatic prostate cancer and
show the potential to apply these tools for biomarker
discovery in cancer and hopefully other disease scenarios.
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